A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension
Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase. The problem of poor blood pressure control is even more serious in elderly hypertensives than in the rest of the population. The antihypertensive drugs of t...
Gespeichert in:
| Veröffentlicht in: | International urology and nephrology 2001, Vol.32 (4), p.519-523 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 523 |
|---|---|
| container_issue | 4 |
| container_start_page | 519 |
| container_title | International urology and nephrology |
| container_volume | 32 |
| creator | Fernández-Vega, F Abellan, J Sanz de Castro, S Cucalón, J M Maceira, B Gómez de la Cámara, A |
| description | Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase. The problem of poor blood pressure control is even more serious in elderly hypertensives than in the rest of the population. The antihypertensive drugs of the AIIRA (non-peptide angiotension II receptor antagonist) class are drugs whose use and experience are increasing and whose properties make them particularly useful in the elderly. We tried to assess the efficacy of treatment with losartan, the first AIIRA drug in a cohort of elderly patients with essential hypertension and to assess the percentage of patients achieving optimum BP control and to evaluate its safety, tolerability and metabolic effects. The intervention proved to be highly effective, achieving the anticipated blood pressure levels in the elderly in 77% of subjects after a 16-week follow-up, with very good tolerability. Renal function remained unchanged, as did the subjects' lipid profile. |
| doi_str_mv | 10.1023/A:1014443020307 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_71309345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71309345</sourcerecordid><originalsourceid>FETCH-LOGICAL-p149t-f16566ade1ff1a78e5726a64543a650ee1febcc849ed92fffe81928c183a00263</originalsourceid><addsrcrecordid>eNpdkE1r3DAURUVIyEymXXdXRBfZOdGTZFnqbhiaDxjIJlkbxX5iFGzJtWSK_30FnW6yenDP4XJ5hHwDdgeMi_v9T2AgpRSMM8GaC7KFuhEVr7W8JNsSQQWKiw25SemDMWY0Y9dkA2C0qYXZkrinKS_9SmOg-YQUnfOd7VZqQ0-TdZgLcnSIyc7ZBuoDxaHHeVjpZLPHkBP94_OJjn7oaY50jIXaXJpSKtTbgZ7WCeeMIfkYvpArZ4eEX893R94efr0enqrjy-PzYX-sJpAmVw5UrZTtEZwD22isG66skrUUVtUMS47vXaelwd5w5xxqMFx3oIVljCuxI7f_eqc5_l4w5Xb0qcNhsAHjktoGBDNC1kX88Un8iMscyraWgwJtmORF-n6WlvcR-3aa_Wjntf3_R_EXLqd1hA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216189042</pqid></control><display><type>article</type><title>A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Fernández-Vega, F ; Abellan, J ; Sanz de Castro, S ; Cucalón, J M ; Maceira, B ; Gómez de la Cámara, A</creator><creatorcontrib>Fernández-Vega, F ; Abellan, J ; Sanz de Castro, S ; Cucalón, J M ; Maceira, B ; Gómez de la Cámara, A</creatorcontrib><description>Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase. The problem of poor blood pressure control is even more serious in elderly hypertensives than in the rest of the population. The antihypertensive drugs of the AIIRA (non-peptide angiotension II receptor antagonist) class are drugs whose use and experience are increasing and whose properties make them particularly useful in the elderly. We tried to assess the efficacy of treatment with losartan, the first AIIRA drug in a cohort of elderly patients with essential hypertension and to assess the percentage of patients achieving optimum BP control and to evaluate its safety, tolerability and metabolic effects. The intervention proved to be highly effective, achieving the anticipated blood pressure levels in the elderly in 77% of subjects after a 16-week follow-up, with very good tolerability. Renal function remained unchanged, as did the subjects' lipid profile.</description><identifier>ISSN: 0301-1623</identifier><identifier>EISSN: 1573-2584</identifier><identifier>DOI: 10.1023/A:1014443020307</identifier><identifier>PMID: 11989539</identifier><identifier>CODEN: IURNAE</identifier><language>eng</language><publisher>Netherlands: Springer Nature B.V</publisher><subject>Aged ; Angiotensin Receptor Antagonists ; Antihypertensive Agents - pharmacology ; Antihypertensive Agents - therapeutic use ; Blood Pressure - drug effects ; Female ; Humans ; Hypertension - drug therapy ; Hypertension - physiopathology ; Losartan - pharmacology ; Losartan - therapeutic use ; Male ; Middle Aged ; Prospective Studies ; Treatment Outcome</subject><ispartof>International urology and nephrology, 2001, Vol.32 (4), p.519-523</ispartof><rights>Copyright (c) 2001 Kluwer Academic Publishers</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11989539$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fernández-Vega, F</creatorcontrib><creatorcontrib>Abellan, J</creatorcontrib><creatorcontrib>Sanz de Castro, S</creatorcontrib><creatorcontrib>Cucalón, J M</creatorcontrib><creatorcontrib>Maceira, B</creatorcontrib><creatorcontrib>Gómez de la Cámara, A</creatorcontrib><title>A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension</title><title>International urology and nephrology</title><addtitle>Int Urol Nephrol</addtitle><description>Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase. The problem of poor blood pressure control is even more serious in elderly hypertensives than in the rest of the population. The antihypertensive drugs of the AIIRA (non-peptide angiotension II receptor antagonist) class are drugs whose use and experience are increasing and whose properties make them particularly useful in the elderly. We tried to assess the efficacy of treatment with losartan, the first AIIRA drug in a cohort of elderly patients with essential hypertension and to assess the percentage of patients achieving optimum BP control and to evaluate its safety, tolerability and metabolic effects. The intervention proved to be highly effective, achieving the anticipated blood pressure levels in the elderly in 77% of subjects after a 16-week follow-up, with very good tolerability. Renal function remained unchanged, as did the subjects' lipid profile.</description><subject>Aged</subject><subject>Angiotensin Receptor Antagonists</subject><subject>Antihypertensive Agents - pharmacology</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Blood Pressure - drug effects</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Losartan - pharmacology</subject><subject>Losartan - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Treatment Outcome</subject><issn>0301-1623</issn><issn>1573-2584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpdkE1r3DAURUVIyEymXXdXRBfZOdGTZFnqbhiaDxjIJlkbxX5iFGzJtWSK_30FnW6yenDP4XJ5hHwDdgeMi_v9T2AgpRSMM8GaC7KFuhEVr7W8JNsSQQWKiw25SemDMWY0Y9dkA2C0qYXZkrinKS_9SmOg-YQUnfOd7VZqQ0-TdZgLcnSIyc7ZBuoDxaHHeVjpZLPHkBP94_OJjn7oaY50jIXaXJpSKtTbgZ7WCeeMIfkYvpArZ4eEX893R94efr0enqrjy-PzYX-sJpAmVw5UrZTtEZwD22isG66skrUUVtUMS47vXaelwd5w5xxqMFx3oIVljCuxI7f_eqc5_l4w5Xb0qcNhsAHjktoGBDNC1kX88Un8iMscyraWgwJtmORF-n6WlvcR-3aa_Wjntf3_R_EXLqd1hA</recordid><startdate>2001</startdate><enddate>2001</enddate><creator>Fernández-Vega, F</creator><creator>Abellan, J</creator><creator>Sanz de Castro, S</creator><creator>Cucalón, J M</creator><creator>Maceira, B</creator><creator>Gómez de la Cámara, A</creator><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7QP</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>2001</creationdate><title>A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension</title><author>Fernández-Vega, F ; Abellan, J ; Sanz de Castro, S ; Cucalón, J M ; Maceira, B ; Gómez de la Cámara, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p149t-f16566ade1ff1a78e5726a64543a650ee1febcc849ed92fffe81928c183a00263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Aged</topic><topic>Angiotensin Receptor Antagonists</topic><topic>Antihypertensive Agents - pharmacology</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Blood Pressure - drug effects</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Losartan - pharmacology</topic><topic>Losartan - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fernández-Vega, F</creatorcontrib><creatorcontrib>Abellan, J</creatorcontrib><creatorcontrib>Sanz de Castro, S</creatorcontrib><creatorcontrib>Cucalón, J M</creatorcontrib><creatorcontrib>Maceira, B</creatorcontrib><creatorcontrib>Gómez de la Cámara, A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>International urology and nephrology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fernández-Vega, F</au><au>Abellan, J</au><au>Sanz de Castro, S</au><au>Cucalón, J M</au><au>Maceira, B</au><au>Gómez de la Cámara, A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension</atitle><jtitle>International urology and nephrology</jtitle><addtitle>Int Urol Nephrol</addtitle><date>2001</date><risdate>2001</risdate><volume>32</volume><issue>4</issue><spage>519</spage><epage>523</epage><pages>519-523</pages><issn>0301-1623</issn><eissn>1573-2584</eissn><coden>IURNAE</coden><abstract>Despite progress in the detection and treatment of hypertension the percentage of patients with controlled hypertension has failed to increase. The problem of poor blood pressure control is even more serious in elderly hypertensives than in the rest of the population. The antihypertensive drugs of the AIIRA (non-peptide angiotension II receptor antagonist) class are drugs whose use and experience are increasing and whose properties make them particularly useful in the elderly. We tried to assess the efficacy of treatment with losartan, the first AIIRA drug in a cohort of elderly patients with essential hypertension and to assess the percentage of patients achieving optimum BP control and to evaluate its safety, tolerability and metabolic effects. The intervention proved to be highly effective, achieving the anticipated blood pressure levels in the elderly in 77% of subjects after a 16-week follow-up, with very good tolerability. Renal function remained unchanged, as did the subjects' lipid profile.</abstract><cop>Netherlands</cop><pub>Springer Nature B.V</pub><pmid>11989539</pmid><doi>10.1023/A:1014443020307</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-1623 |
| ispartof | International urology and nephrology, 2001, Vol.32 (4), p.519-523 |
| issn | 0301-1623 1573-2584 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71309345 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Aged Angiotensin Receptor Antagonists Antihypertensive Agents - pharmacology Antihypertensive Agents - therapeutic use Blood Pressure - drug effects Female Humans Hypertension - drug therapy Hypertension - physiopathology Losartan - pharmacology Losartan - therapeutic use Male Middle Aged Prospective Studies Treatment Outcome |
| title | A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T16%3A23%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20study%20on%20the%20efficacy%20and%20safety%20of%20losartan%20in%20elderly%20patients%20with%20mild%20to%20moderate%20essential%20hypertension&rft.jtitle=International%20urology%20and%20nephrology&rft.au=Fern%C3%A1ndez-Vega,%20F&rft.date=2001&rft.volume=32&rft.issue=4&rft.spage=519&rft.epage=523&rft.pages=519-523&rft.issn=0301-1623&rft.eissn=1573-2584&rft.coden=IURNAE&rft_id=info:doi/10.1023/A:1014443020307&rft_dat=%3Cproquest_pubme%3E71309345%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216189042&rft_id=info:pmid/11989539&rfr_iscdi=true |